Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma

Abroad (travel likely)RecruitingPHASE3

Conditions

Multiple Myeloma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • Cross Cancer Institute, Edmonton, Alberta, Canada

    Contact: Study coordinator (Steven Shih)
  • BCCA - Kelowna, Kelowna, British Columbia, Canada

    Contact: Study coordinator (Erma Gardner) · 250 712-3900
  • BCCA - Vancouver, Vancouver, British Columbia, Canada

    Contact: Study coordinator (Christopher Venner)
  • CancerCare Manitoba, Winnipeg, Manitoba, Canada

    Contact: Study coordinator (Rami R. Kotb) · 204 787-2108
  • The Moncton Hospital, Moncton, New Brunswick, Canada

    Contact: Study coordinator (Nizar Abdel-Samad) · 506 870-2404
  • Regional Health Authority B, Zone 2, Saint John, New Brunswick, Canada

    Contact: Study coordinator (Anthony J. Reiman) · 506 648-6884
  • Dr. H. Bliss Murphy Cancer Centre, St. John's, Newfoundland and Labrador, Canada

    Contact: Study coordinator (Debra Bergstrom) · 709 777-7557
  • Royal Victoria Regional Health Centre, Barrie, Ontario, Canada

    Contact: Study coordinator (Rouslan Kotchetkov)
  • William Osler Health System, Brampton, Ontario, Canada

    Contact: Study coordinator (Savannah Norman) · 416 494-2120
  • Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada

    Contact: Study coordinator (Hira Mian) · 905 387-9495
  • Kingston Health Sciences Centre, Kingston, Ontario, Canada

    Contact: Study coordinator (Bethany Monteith)
  • Waterloo Regional Health Network (WRHN), Kitchener, Ontario, Canada

    Contact: Study coordinator (Armela Dicu) · 519 749-4370
  • London Health Sciences Centre Research Inc., London, Ontario, Canada

    Contact: Study coordinator (Martha Louzada) · 519 685-2391
  • Stronach Regional Health Centre at Southlake, Newmarket, Ontario, Canada

    Contact: Study coordinator (Peter James Anglin) · 905 895-4521
  • Lakeridge Health Oshawa, Oshawa, Ontario, Canada

    Contact: Study coordinator (Ariah Joshua Schattner) · 905 576-8711
  • Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

    Contact: Study coordinator (Arleigh B. Robertson McCurdy) · 613 737-7700
  • Algoma District Cancer Program, Sault Ste. Marie, Ontario, Canada

    Contact: Study coordinator (Danny Hill) · 705 759-3434
  • Niagara Health System, St. Catharines, Ontario, Canada

    Contact: Study coordinator (Huma Qawi) · 905 684-7271
  • St. Michael's Hospital, Toronto, Ontario, Canada

    Contact: Study coordinator (Martina Trinkaus) · 416 864-5632
  • St. Joseph's Health Centre, Toronto, Ontario, Canada

    Contact: Study coordinator (Christie Kim)
  • Windsor Regional Cancer Centre, Windsor, Ontario, Canada

    Contact: Study coordinator (Sindu Mary Kanjeekal) · 519 253-5253
  • CIUSSS de l'Est-de-I'lle-de-Montreal, Montreal, Quebec, Canada

    Contact: Study coordinator (Richard LeBlanc) · 514 252-3400
  • The Jewish General Hospital, Montreal, Quebec, Canada

    Contact: Study coordinator (Rayan Kaedbey) · 614 340-8222
  • St. Mary's Hospital, Montreal, Quebec, Canada

    Contact: Study coordinator (Tanya Skamene) · 514 340-8222
  • The Research Institute of the McGill University, Montreal, Quebec, Canada

    Contact: Study coordinator (Michael Sebag) · 514 398-8307
  • CHU de Quebec-Hopital l'Enfant-Jesus (HEJ), Québec, Quebec, Canada

    Contact: Study coordinator (Julie Cote) · 418 525-4444
  • Allan Blair Cancer Centre, Regina, Saskatchewan, Canada

    Contact: Study coordinator (Ibraheem Mohammed Othman) · 306 766-2691
  • Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada

    Contact: Study coordinator (Julie Stakiw) · 306 655-2980
Study leads
  • Hira Mian

    Study Chair

    Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario Canada